Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

he histamine H3 receptor for the treatment of narcolepsy with cataplexy. In this randomized, double-blind, placebo-controlled trial in 24 healthy volunteers, APD916 demonstrated dose-proportional pharmacokinetic exposure over the tested dose range.

Outlook for 2011Arena expects to use cash and cash equivalents of approximately $78 to $84 million for its operating activities and interest expense in 2011, and approximately $2 million for capital expenditures. In January 2011, Arena prepaid the $20 million payment that was due to Deerfield in July 2011. Assuming no additional capital from collaborators, investors or other sources, Arena would expect to end 2011 with approximately $45 million to $51 million.

Scheduled Earnings Call Arena will host both a conference call and webcast to discuss the fourth quarter and full year 2010 financial results and to provide a business and financial update today, Friday, March 11, 2011, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Fourth Quarter and Full Year 2010 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammato
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... Oligomerix, Inc. , a privately held company pioneering the ... and related neurodegenerative disorders, announced today the relocation of ... as of January 15, 2014 and expanded lease ... College. Oligomerix, which is focused on the ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
(Date:4/17/2014)... patients adrenaline after they suffer a cardiac arrest outside ... surviving long-term, according to new research conducted at St. ... have a cardiac arrest get adrenaline, which has been ... said Dr. Steve Lin, an emergency physician and trauma ... medical treatment, long-term survival rates of patients who suffer ...
(Date:4/17/2014)... as the leading weapon against the deadly disease could ... research indicating it simply needs to be administered differently. ... cheap anti-malarial drug chloroquine in treating and preventing the ... half a million people each year around the world. ... to chloroquine, but research carried out at the Australian ...
(Date:4/16/2014)... Consider the marvel of the embryo. It begins as ... as they multiply to become the cells of our lungs, ... body. , Now, in a feat of reverse tissue engineering, ... coding that allows embryonic cells to proliferate and transform into ...
(Date:4/16/2014)... Therapeutics, Inc. (NASDAQ: CLDX) announced today that final data ... tumors, including long-term patient follow-up, have been published in ... The data demonstrate robust antibody and T cell responses ... advanced cancers and suggest that CDX-1401 may predispose patients ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... French and Spanish . , Researchers at ... ,gene E, which leads to the death of tumour cells derived from ... this new gene is that its use to fight cancer can reduce ... effective treatment for cancer. This research was conducted by Ana ...
... ... Surgeons (ASPS), are available to discuss the recently proposed cosmetic surgery tax. , ... Arlington Heights, IL (Vocus) ... Surgeons (ASPS), are available to discuss the recently proposed cosmetic surgery tax., , ,WHAT: ...
... ... IVD manufacturers, distributors and industry service providers about the state of their company, international ... ... medical device regulatory consulting firm Emergo Group Inc. recently surveyed medical device and ...
... ... in a national movement to raise awareness for a disease that affects 24 million Americans. ... Richmond, VA (Vocus) November ... recognizes National Diabetes Awareness Month, observed annually during the month of November. Nearly 24 ...
... ... report on how to generate free leads through your website. , ... (PRWEB) November 24, 2009 -- 2009 has been another ... the strain to keep their businesses afloat and reduce costs. Typically the first items on ...
... , RESTON, Va., Nov. 24 Lincoln County ... Maine with two small hospitals and retirement communities, employing more than 1,200 ... you,re not getting successful backup, you,re not doing your job," says Brooks ... case with many hospitals in Maine, budgets are extremely tight for LCH, ...
Cached Medicine News:Health News:Gene increases effectiveness of drugs used to fight cancer and allows reduction in dosage 2Health News:Leading Plastic Surgery Experts Available to Discuss Proposed ,Cosmetic Surgery Tax 2Health News:Medical Device Industry Positive About 2010 – Survey 2Health News:Home Care Delivered, Inc. Recognizes November as National Diabetes Awareness Month 2Health News:Home Care Delivered, Inc. Recognizes November as National Diabetes Awareness Month 3Health News:We Do Web Content Offers Free Lead Generation Report 2Health News:We Do Web Content Offers Free Lead Generation Report 3Health News:Replay 4 Customer Takes Risk, Fights for Budget to Protect Information Systems 2
HST, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit....
This convex sector mechanical sector transducer provides real-time photo-realistic images....
Wide band, Super High Density endovaginal transducer provides a 180 field of view allowing imaging of the entire uterus and cervix with minimal transducer movement....
Provides tremendous image quality along with a 180 degree field of view....
Medicine Products: